Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 18:00 save search
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
IMNM | $15.5 -9.78% -10.84% 2.1M
|
Health Technology
|
| O: 0.0%
H: 6.46%
C: 5.79%
al102 treatment acquisition
Global Hemophilia Market Analysis Report 2023-2028: Increased Focus on Prophylactic Treatment and Shifting Focus to Extended Half Life Therapies
Published: 2024-03-07 (Crawled : 18:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
report life treatment global market
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
opl-0401 health treatment study diabetic
Global Venous Thromboembolism Treatment Market to Reach $4.40 Billion by 2030, as Demand for Minimally Invasive Procedures Grows
Published: 2024-02-26 (Crawled : 18:00) - prnewswire.com
SYK | $325.43 -0.62% 0.0% 1.8M
|
Health Technology
|
| O: 0.09%
H: 0.03%
C: -0.81%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.21%
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: -0.35%
H: 0.45%
C: 0.15%
CAH | $108.19 2.07% 0.0% 1.5M
|
Distribution Services
|
| O: 1.53%
H: 1.17%
C: 0.5%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: 0.1%
H: 0.37%
C: -0.6%
ANGO | $6.26 2.29% 2.24% 480K
|
Health Technology
|
| O: -0.69%
H: 2.78%
C: 1.57%
reach treatment global market
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
SHPH | $0.409 1.89% 1.86% 12K
|
|
| O: 4.42%
H: 0.0%
C: -16.11%
fda approval treatment pharmaceuticals trial glioblastoma
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
Published: 2024-01-03 (Crawled : 18:00) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.84%
H: 1.72%
C: -10.24%
ino-3107 approval treatment program potential
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
Published: 2023-12-26 (Crawled : 18:00) - globenewswire.com
RTGN | $3.09 203.88% 400
|
n/a
| Email alert
Add to watchlist
services macular diagnostic review treatment medical study
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
Published: 2023-12-20 (Crawled : 18:00) - biospace.com/
COSM 4 | $0.4839 -20.37% -25.58% 670K
|
Wholesale Trade
|
| O: -4.79%
H: 2.88%
C: -7.91%
health treatment acquire diabetes agreement
Global Melanoma Treatment Market Report 2023, Featuring Comprehensive Profiles of Leading Players including Amgen, Roche, Merck & Co., Pfizer Inc., BMS and Novartis
Published: 2023-12-13 (Crawled : 18:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.67%
H: 1.17%
C: 0.85%
ARMK | $31.87 2.15% 0.0% 3.2M
|
Consumer Services
|
| O: 0.88%
H: 1.88%
C: 0.69%
melanoma report merck treatment global novartis market
Global Myasthenia Gravis Treatment Market Report 2023 - Opportunities in Tailored Treatment Approaches, Biologics and Immunotherapies and Patient-Centric Care
Published: 2023-12-06 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.64%
H: 0.0%
C: -1.33%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.03%
H: 0.28%
C: -0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
report treatment care global market
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Published: 2023-12-01 (Crawled : 18:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: 20.86%
H: 21.75%
C: -2.13%
SPRC | $1.235 -4.26% -4.45% 150K
|
Manufacturing
|
| O: 22.92%
H: 2.08%
C: -17.08%
obesity drug pre-clinical positive trial results
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
Wastewater Treatment Services Markets: Designing and Engineering Consulting, Building and Installation Services - Global Forecast to 2028
Published: 2023-11-17 (Crawled : 18:00) - prnewswire.com
ECL | News | $218.16 -0.48% 0.69% 2.6M
|
Process Industries
| Email alert
Add to watchlist
XYL | $127.84 0.53% 0.0% 2.2M
|
Producer Manufacturing
| Email alert
Add to watchlist
installation services treatment global
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
Published: 2023-11-06 (Crawled : 18:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
avb-101 fda treatment dementia clearance designation
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Published: 2023-11-03 (Crawled : 18:00) - biospace.com/
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: 2.46%
H: 9.49%
C: 2.4%
publication cell treatment meeting
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
A large international study of migraine reveals new biological pathways for treatment
Published: 2023-10-26 (Crawled : 18:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.24%
H: 0.71%
C: -0.66%
international treatment migraine study
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
Published: 2023-10-05 (Crawled : 18:00) - biospace.com/
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 2.04%
H: 2.23%
C: 2.08%
children treatment results study
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Published: 2023-09-18 (Crawled : 18:00) - biospace.com/
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: -1.33%
H: 2.56%
C: 2.03%
drug breast treatment women therapeutics
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Published: 2023-09-05 (Crawled : 18:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: 0.0%
H: 7.57%
C: 0.86%
guardant360 lung japan diagnostic health her2 approval cancer cell treatment companion
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.